 CureVac NV NASDAQ: CVAC slipped about 45 in the stock market on Thursday morning as the company said the late-stage trial showed its candidate COVID-19 vaccine to be only 47 effective, raising questions on the German biotechs agreement with the European Union to deliver hundreds of millions of doses of its vaccine CVnCoV. CureVacs shot ... The post CureVac collapses 45 after disappointing results from COVID-19 vaccine trial appeared first on Invezz. 